Peptech: Continuing royalties fuel steady income;price target $2.20 BTA: Winning laswsuit with Glaxo and royalties for forseeable future; targeT $3.30 A SHARE Mayne;de-merger and concentration on high margined pharma and oncology products may result in bidding with either Pfizer or Sanofi for possible acquisition of Sirtex as purpose of selling hospital divisions was for acquisition of smaller biotech and niche pharma cos. After run up to around 3.60 from 2.225 a share based on improving fundamentals and big turnaround at Sirtex, Dr Gray, Hunter Hall and instos that own collectively about 86 % of co let company be acquired north of previous Cehalon bid of $4.75 a share. These are my predictions only and due your own homework and due diligence, but I feel I am entitled to my own opinion after being in the industry over 25 years. LHG:gold rALLY CONTINUES ALBEiT AT A LESS FERVERISH PACE AND lhG HAS ANOTHER 25 % UP IN IT
